CCS Antibody



PACO20578

Product Information

Size:

50ul

Reactivity:

Human, Mouse, Rat

Source:

Rabbit

Isotype:

lgG

Applications:

ELISA, WB, IHC

Recommended dilutions:

ELISA:1:1000-1:2000, WB:1:200-1:1000, IHC:1:25-1:100

Protein Background:

Cytoplasmic potassium channel subunit that modulates the characteristics of the channel-forming alpha-subunits. Modulates action potentials via its effect on the poreforming alpha subunits. Promotes expression of the pore-forming alpha subunits at the cell membrane, and thereby increases channel activity. Mediates closure of delayed rectifier potassium channels by physically obstructing the pore via its N-terminal domain and increases the speed of channel closure for other family members. Promotes the closure of KCNA1, KCNA2 and KCNA5 channels. Accelerates KCNA4 channel closure. Accelerates the closure of heteromeric channels formed by KCNA1 and KCNA4. Accelerates the closure of heteromeric channels formed by KCNA2, KCNA5 and KCNA6. Isoform KvB1.2 has no effect on KCNA1, KCNA2 or KCNB1. Enhances KCNB1 and KCNB2 channel activity. Binds NADPH; this is required for efficient down-regulation of potassium channel activity.

Gene ID:

CCS

Uniprot

O14618

Synonyms:

copper chaperone for superoxide dismutase


Immunogen:


Synthetic peptide of human CCS.

Storage:


-20° C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol

Product Images






The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using PACO20578(CCS Antibody) at dilution 1/30, on the right is treated with synthetic peptide. (Original magnification: x—200).



Gel: 10%SDS-PAGE, Lysate: 40 ug, Lane 1-3: 293T cells, hepg2 cells, human fetal liver tissue, Primary antibody: PACO20578(CCS Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 minutes.



The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using PACO20578(CCS Antibody) at dilution 1/30, on the right is treated with synthetic peptide. (Original magnification: x—200).